Evaluation of Vitamin D Analogs as Therapeutic Agents for Prostate Cancer (original) (raw)
References
American Cancer Society, Inc., Cancer Facts & Figures 2002 (2002) American Cancer Society, Atlanta, Georgia, pp 3–15 Google Scholar
Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF (1998) Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporosis Int 8:222–230 ArticleCAS Google Scholar
Barreto A, Schwartz GG, Woodruff P, Cramer SD (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary cultures of prostate epithelial cells. Cancer Epidemiol Biomark Prev 9:265–270 CAS Google Scholar
Binderup L, Binderup E, Gotfredsen WO (1997) Development of new vitamin D analogs. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 1027–1043 Google Scholar
Breslau NA, Zerwekh JE (1997) Pharmacology of vitamin D preparations. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 607–618 Google Scholar
Byne PM, Freaney R, McKenna MJ (1995) Vitamin D supplementation of the elderly: review of safety and effectiveness of various regimes. Calcif Tissue Int 56:518–520 Article Google Scholar
Campbell MJ, Koeffler HP (1997) Toward the intervention of cancer with vitamin D Compounds. J Natl Cancer Inst 89:182–183 ArticlePubMedCAS Google Scholar
Chen TC, Holick MF (2000) Hexafluoro-1,25-dihydroxyvitamin D3 has markedly increased potency in inhibiting proliferation of cultured human keratinocytes compared with 1,25-dihydroxyvitamin D3. Br J Dermatol 143:72–78 ArticlePubMedCAS Google Scholar
Chen TC, Young MV, Whitlatch LW, Zhu XH, Kong XF, Schwartz GG, Lokeshwar BL, Holick MF (1998) Expression and regulation of 25-hydroxyvitamin D3–1-alpha-hydroxylase in cultured human prostatic cells. Bone 23 [Suppl 5]: S262 Google Scholar
Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF (2000a) The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1a,25-dihydroxyvitamin D2 for prostate cancer therapy. Clin Cancer Res 6:901–908 CAS Google Scholar
Chen TC, Whitlatch LW, Young MV, Flanagan JN, Schwartz GG, Lokeshwar BL, Kong XF, Xue P, Holick MF (2000b) Enhancement of 25-hydroxyvitamin D-1-alpha-hydroxylase activity in prostate cells by gene transfection: a novel approach for the treatment of prostate cancer. Vitamin D Endocrine Systsem: Structural, Biological, Genetic and Clinical Aspects. In: Norman AW, Bouillon R, Thomasset M (eds) Proceedings of the Eleventh workshopon vitamin D, Nashville, TN, May 27-June 1, 2000. University of California, Riversidepp 525–528 Google Scholar
Dusso A, Brown A, Slatopolsky E (1994) Extrarenal production of calcitriol. Semin Nephrol14:144–155 Google Scholar
Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-Dihydroxyvitamin D3 (calcitriol). J Urol 159:2035–2040 ArticlePubMedCAS Google Scholar
Hanchette CL, Schwartz GG (1992) Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 70:2861–2869 ArticlePubMedCAS Google Scholar
Hansen CM, Hamberg KJ, Binderup E, Binderup L (2000) Seocalcitol (EB 1089): a vitamin Danalogue of anti-cancer potential, background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 6:803–828 ArticlePubMedCAS Google Scholar
Hsu JY, Feldman D, McNeal JE, Peehl DM (2001) Reduced 1a-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-inducedgrowth inhibition. Cancer Res 61:2852–2856 PubMedCAS Google Scholar
Hughes MR, Baylink DJ, Jones OG, Haussler M (1976) Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. J Clin Invest 58:61–70 ArticlePubMedCAS Google Scholar
Inaba M, Okuno S, Nishizawa Y, Inoue A, Nishiawa Y, Morii H, DeLuca HF (1989) DNA binding property of vitamin D3 receptors associated with 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Arch Biochem Biophys 268:35–39 ArticlePubMedCAS Google Scholar
Isaacs JT, Isaacs WB, Feitz WF, Scheres J (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9:261–281 ArticlePubMedCAS Google Scholar
Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmex J, Arruda J, Lau A, Slatolpolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue:19-nor-1,25-Dihydroxyvitamin D2. Am J Kideny Dis 32 [Suppl2]: S48–S54 ArticleCAS Google Scholar
Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang S-H, Block NL, Binderup L (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB 1089. Cancer Epidemiol Biomark Prev 8:241–248 CAS Google Scholar
MacDonald PN (1999) Molecular BIOLOGY OF THE VITAMIN D receptor. In: Holick MF (ed) Vitamin D: molecular biology, physiology, and clinical applications. Humana Press, Totowa, New Jersey, pp 109–128 Google Scholar
Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-nor-1,25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427–1432 PubMedCAS Google Scholar
Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P (1992) The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25-dihydroxyvitamin D3. Cancer Res 52:515–520 PubMedCAS Google Scholar
Moffatt KA, Johannes WU, Miller GJ (1999) 1a,25-Dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695–703 PubMedCAS Google Scholar
Nakatsuka K, Imanishi Y, Morishima Y, Sekiya K, Sasao K, Miki T, Nishizawa Y, Katsumata T, Nagata A, Murakawa S, Morii H (1992) Biological potency of a fluorinated vitamin D analogue in hypoparathyroidism. Bone Miner 16:73–81 ArticlePubMedCAS Google Scholar
Napoli JL, Fivizzani MA, Schnoes HK, DeLuca HF (1978) 1-a-hydroxy-25-fluorovitamin D3. V. A potent analogue of 1a,25-dihydroxyvitamin D3. Biochemistry 17:2387–2392 ArticlePubMedCAS Google Scholar
Oikawa T, Yoshida Y, Shimamura M, Ashino-Fuse H, Iwaguchi T, Tominaga T (1991) Antitumor effect of 22-oxa-1a,25-dihydroxyvitamin D3: a potent angiogenesis inhibitor on ratmammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 2:475–480 ArticlePubMedCAS Google Scholar
Omdahl JL, Morris HA, May BK (2002) Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 22:139–166 ArticlePubMedCAS Google Scholar
Osborn JL, Schwartz GG, Bahnson R, Smith DC, Trump DL (1995) Phase II trial of oral 1,25-Dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195–198 ArticlePubMedCAS Google Scholar
Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D (1994) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805–810 PubMedCAS Google Scholar
Sasaki H, Harada H, Handa Y, Morino H, Suzawa M, Shimpo E, Katsumata T, Masuhiro Y, Matsuda K, Ebihara K (1995) Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. Biochemistry 34:370–377 ArticlePubMedCAS Google Scholar
Schwartz GG, Wang MH, Zhang M, Singh RJ, Siegal GP (1997) 1a,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prev 6:727–732 CAS Google Scholar
Schwartz GG (1992) Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology 11:244–254 ArticlePubMedCAS Google Scholar
Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10:1307–1311 PubMedCAS Google Scholar
Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR (1994) Human prostate cancer cell lines: inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077–1081 PubMedCAS Google Scholar
Schwartz GG, Hill CC, Oele TA, Becich MJ, Bahnson RR (1995) 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46:365–369 ArticlePubMedCAS Google Scholar
Schwartz GG, Wang M-H, Zhang M, Singh, RJ, Siegal GP (1997) 1a,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prev 6:727–732 CAS Google Scholar
Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxy vitamin D3. Cancer Epidemiol Biomark Prev 7:391–395 CAS Google Scholar
Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952–1960 ArticlePubMedCAS Google Scholar
Skowronski RJ, Peehl DM, Feldman D (1995) Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 136:20–26 ArticlePubMedCAS Google Scholar
Tanaka Y, DeLuca HF, Kobayashi Y, Ikekawa N (1984) 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: a high potent, long-lasting analog of 1,25-dihydroxyvitamin D3. Arch Biochem Biophys 229: 348–354 ArticlePubMedCAS Google Scholar
Taplin ME, Ho SM (2001) The endocrinology of prostate cancer. J Clin Endocrinol Metab 86:3467–3477 ArticlePubMedCAS Google Scholar
Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC (2002) 25-Hydroxyvitamin D-1a-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81:135–140 ArticleCAS Google Scholar
Zhuang S-H, Burnstein KL (1998) Antiproliferative effect of 1a,25-dihydroxyvitamin D3 in human prostate cancer cell line LplayNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197–1207 ArticlePubMedCAS Google Scholar
Zhuang S-H, Schwartz GG, Cameron D, Burnstein KL (1997) Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83–90 ArticlePubMedCAS Google Scholar